for Journals by Title or ISSN
for Articles by Keywords
help
Followed Journals
Journal you Follow: 0
 
Sign Up to follow journals, search in your chosen journals and, optionally, receive Email Alerts when new issues of your Followed Journals are published.
Already have an account? Sign In to see the journals you follow.
Journal Cover The Lancet Oncology
  [SJR: 13.94]   [H-I: 197]   [160 followers]  Follow
    
   Full-text available via subscription Subscription journal
   ISSN (Print) 1470-2045 - ISSN (Online) 1474-5488
   Published by Elsevier Homepage  [3175 journals]
  • Genetic testing for young women with breast cancer
    • Authors: Kelly Metcalfe; Mohammad R Akbari; Steven A Narod
      Abstract: Publication date: April 2018
      Source:The Lancet Oncology, Volume 19, Issue 4
      Author(s): Kelly Metcalfe, Mohammad R Akbari, Steven A Narod


      PubDate: 2018-04-12T09:29:51Z
      DOI: 10.1016/s1470-2045(18)30162-1
       
  • Genetic testing for young women with breast cancer – Authors' reply
    • Authors: Diana M Eccles; Ellen R Copson
      Abstract: Publication date: April 2018
      Source:The Lancet Oncology, Volume 19, Issue 4
      Author(s): Diana M Eccles, Ellen R Copson


      PubDate: 2018-04-12T09:29:51Z
      DOI: 10.1016/s1470-2045(18)30205-5
       
  • Possible X chromosome-linked transmission of ovarian cancer
    • Authors: Priya Venkatesan
      Abstract: Publication date: April 2018
      Source:The Lancet Oncology, Volume 19, Issue 4
      Author(s): Priya Venkatesan


      PubDate: 2018-04-12T09:29:51Z
      DOI: 10.1016/s1470-2045(18)30183-9
       
  • Ultra-processed foods might increase cancer risk
    • Authors: Elizabeth Gourd
      Abstract: Publication date: April 2018
      Source:The Lancet Oncology, Volume 19, Issue 4
      Author(s): Elizabeth Gourd


      PubDate: 2018-04-12T09:29:51Z
      DOI: 10.1016/s1470-2045(18)30184-0
       
  • Larotrectinib in TRK fusion-positive cancers
    • Authors: Talha Khan Burki
      Abstract: Publication date: April 2018
      Source:The Lancet Oncology, Volume 19, Issue 4
      Author(s): Talha Khan Burki


      PubDate: 2018-04-12T09:29:51Z
      DOI: 10.1016/s1470-2045(18)30190-6
       
  • New interventions offer prostate cancer hope
    • Authors: The Lancet Oncology
      First page: 427
      Abstract: Publication date: April 2018
      Source:The Lancet Oncology, Volume 19, Issue 4
      Author(s): The Lancet Oncology


      PubDate: 2018-04-12T09:29:51Z
      DOI: 10.1016/s1470-2045(18)30219-5
       
  • Nedaplatin in nasopharyngeal cancer: the rebirth of platinum salts'
    • Authors: Pierre Blanchard; Yungan Tao
      Pages: 429 - 431
      Abstract: Publication date: April 2018
      Source:The Lancet Oncology, Volume 19, Issue 4
      Author(s): Pierre Blanchard, Yungan Tao


      PubDate: 2018-04-12T09:29:51Z
      DOI: 10.1016/s1470-2045(18)30113-x
       
  • Adjuvant aromatase inhibition: more options for patients
    • Authors: Luc Y Dirix
      Pages: 431 - 432
      Abstract: Publication date: April 2018
      Source:The Lancet Oncology, Volume 19, Issue 4
      Author(s): Luc Y Dirix


      PubDate: 2018-04-12T09:29:51Z
      DOI: 10.1016/s1470-2045(18)30155-4
       
  • Can umbralisib bring PI3Kδ out of the shadows'
    • Authors: Jacqueline C Barrientos
      Pages: 432 - 434
      Abstract: Publication date: April 2018
      Source:The Lancet Oncology, Volume 19, Issue 4
      Author(s): Jacqueline C Barrientos


      PubDate: 2018-04-12T09:29:51Z
      DOI: 10.1016/s1470-2045(18)30154-2
       
  • Addition of platinum salts to neoadjuvant chemotherapy in triple-negative
           breast cancer: a new standard of care'
    • Authors: Giuseppe Curigliano
      Pages: 434 - 436
      Abstract: Publication date: April 2018
      Source:The Lancet Oncology, Volume 19, Issue 4
      Author(s): Giuseppe Curigliano


      PubDate: 2018-04-12T09:29:51Z
      DOI: 10.1016/s1470-2045(18)30129-3
       
  • The brim of uncertainty in adjuvant treatment of melanoma
    • Authors: Allison Betof Warner; Michael A Postow
      Pages: 436 - 437
      Abstract: Publication date: April 2018
      Source:The Lancet Oncology, Volume 19, Issue 4
      Author(s): Allison Betof Warner, Michael A Postow


      PubDate: 2018-04-12T09:29:51Z
      DOI: 10.1016/s1470-2045(18)30150-5
       
  • Predicting early relapse in follicular lymphoma: have we turned a
           corner'
    • Authors: Shamzah Araf; Jessica Okosun; Jude Fitzgibbon
      Pages: 441 - 442
      Abstract: Publication date: April 2018
      Source:The Lancet Oncology, Volume 19, Issue 4
      Author(s): Shamzah Araf, Jessica Okosun, Jude Fitzgibbon


      PubDate: 2018-04-12T09:29:51Z
      DOI: 10.1016/s1470-2045(18)30114-1
       
  • Adjuvant therapy in colon cancer: less is more
    • Authors: David H Ilson
      Pages: 442 - 443
      Abstract: Publication date: April 2018
      Source:The Lancet Oncology, Volume 19, Issue 4
      Author(s): David H Ilson


      PubDate: 2018-04-12T09:29:51Z
      DOI: 10.1016/s1470-2045(18)30127-x
       
  • The NHS and migrant patients with cancer
    • Authors: Sophie Williams; Erin Dexter; Jessica L Potter
      Pages: 444 - 445
      Abstract: Publication date: April 2018
      Source:The Lancet Oncology, Volume 19, Issue 4
      Author(s): Sophie Williams, Erin Dexter, Jessica L Potter


      PubDate: 2018-04-12T09:29:51Z
      DOI: 10.1016/s1470-2045(18)30152-9
       
  • Guidelines for sub-Saharan Africa: a call for evidence
    • Authors: Matthew Painschab; Satish Gopal
      Pages: 445 - 446
      Abstract: Publication date: April 2018
      Source:The Lancet Oncology, Volume 19, Issue 4
      Author(s): Matthew Painschab, Satish Gopal


      PubDate: 2018-04-12T09:29:51Z
      DOI: 10.1016/s1470-2045(18)30124-4
       
  • Slogans and donor pages of cancer centres: do they convey discordant
           messages'
    • Authors: Ezra Hahn; Dan Ariely; Ian Tannock; Anthony Fyles; Benjamin W Corn
      Pages: 447 - 448
      Abstract: Publication date: April 2018
      Source:The Lancet Oncology, Volume 19, Issue 4
      Author(s): Ezra Hahn, Dan Ariely, Ian Tannock, Anthony Fyles, Benjamin W Corn


      PubDate: 2018-04-12T09:29:51Z
      DOI: 10.1016/s1470-2045(18)30203-1
       
  • Opportunities for improving oncology care
    • Authors: Karen L Syrjala
      First page: 449
      Abstract: Publication date: April 2018
      Source:The Lancet Oncology, Volume 19, Issue 4
      Author(s): Karen L Syrjala


      PubDate: 2018-04-12T09:29:51Z
      DOI: 10.1016/s1470-2045(18)30208-0
       
  • The rise and fall of the wellness warriors
    • Authors: Robert Stirrups
      First page: 450
      Abstract: Publication date: April 2018
      Source:The Lancet Oncology, Volume 19, Issue 4
      Author(s): Robert Stirrups


      PubDate: 2018-04-12T09:29:51Z
      DOI: 10.1016/s1470-2045(18)30207-9
       
  • Sarcopenia and adiposity linked to overall survival
    • Authors: Elizabeth Gourd
      Abstract: Publication date: Available online 12 April 2018
      Source:The Lancet Oncology
      Author(s): Elizabeth Gourd


      PubDate: 2018-04-15T09:35:26Z
      DOI: 10.1016/s1470-2045(18)30284-5
       
  • A CRITICal period for chemoradiotherapy in gastric cancer
    • Authors: Trevor Leong
      Abstract: Publication date: Available online 9 April 2018
      Source:The Lancet Oncology
      Author(s): Trevor Leong


      PubDate: 2018-04-12T09:29:51Z
      DOI: 10.1016/s1470-2045(18)30153-0
       
  • Targeting EZH2 with tazemetostat
    • Authors: Shinichi Makita; Kensei Tobinai
      Abstract: Publication date: Available online 9 April 2018
      Source:The Lancet Oncology
      Author(s): Shinichi Makita, Kensei Tobinai


      PubDate: 2018-04-12T09:29:51Z
      DOI: 10.1016/s1470-2045(18)30149-9
       
  • Lawsuit filed against FDA for not reviewing e-cigarettes
    • Authors: Priya Venkatesan
      Abstract: Publication date: Available online 6 April 2018
      Source:The Lancet Oncology
      Author(s): Priya Venkatesan


      PubDate: 2018-04-12T09:29:51Z
      DOI: 10.1016/s1470-2045(18)30274-2
       
  • Short vs long course adjuvant chemotherapy for colon cancer
    • Authors: Ashray Gunjur
      Abstract: Publication date: Available online 6 April 2018
      Source:The Lancet Oncology
      Author(s): Ashray Gunjur


      PubDate: 2018-04-12T09:29:51Z
      DOI: 10.1016/s1470-2045(18)30272-9
       
  • Oncologists burnout in the spotlight
    • Authors: Talha Khan Burki
      Abstract: Publication date: Available online 6 April 2018
      Source:The Lancet Oncology
      Author(s): Talha Khan Burki


      PubDate: 2018-04-12T09:29:51Z
      DOI: 10.1016/s1470-2045(18)30275-4
       
  • Health care for cancer survivors in the USA
    • Authors: Manjulika Das
      Abstract: Publication date: Available online 6 April 2018
      Source:The Lancet Oncology
      Author(s): Manjulika Das


      PubDate: 2018-04-12T09:29:51Z
      DOI: 10.1016/s1470-2045(18)30271-7
       
  • Combining top-ranked immunotherapeutics in lung cancer
    • Authors: Christian Rolfo; Evelien L J Smits
      Abstract: Publication date: Available online 5 April 2018
      Source:The Lancet Oncology
      Author(s): Christian Rolfo, Evelien L J Smits


      PubDate: 2018-04-12T09:29:51Z
      DOI: 10.1016/s1470-2045(18)30186-4
       
  • Tivantinib for advanced hepatocellular carcinoma: is MET still a viable
           target'
    • Authors: Colin D Weekes; Jeffrey W Clark; Andrew X Zhu
      Abstract: Publication date: Available online 3 April 2018
      Source:The Lancet Oncology
      Author(s): Colin D Weekes, Jeffrey W Clark, Andrew X Zhu


      PubDate: 2018-04-12T09:29:51Z
      DOI: 10.1016/s1470-2045(18)30249-3
       
  • Correction to Lancet Oncol 2013; 14: 1067–76
    • Abstract: Publication date: April 2018
      Source:The Lancet Oncology, Volume 19, Issue 4


      PubDate: 2018-04-12T09:29:51Z
       
  • Correction to Lancet Oncol 2017; 18: 1221–37
    • Abstract: Publication date: April 2018
      Source:The Lancet Oncology, Volume 19, Issue 4


      PubDate: 2018-04-12T09:29:51Z
       
  • Correction to Lancet Oncol 2018; 19: 295–309
    • Abstract: Publication date: April 2018
      Source:The Lancet Oncology, Volume 19, Issue 4


      PubDate: 2018-04-12T09:29:51Z
       
  • Correction to Lancet Oncol 2018; 19: 434–36
    • Abstract: Publication date: April 2018
      Source:The Lancet Oncology, Volume 19, Issue 4


      PubDate: 2018-04-12T09:29:51Z
       
  • Correction to Lancet Oncol 2018; 19: 474–85
    • Abstract: Publication date: April 2018
      Source:The Lancet Oncology, Volume 19, Issue 4


      PubDate: 2018-04-12T09:29:51Z
       
  • Correction to Lancet Oncol 2018; 19: 510–20
    • Abstract: Publication date: April 2018
      Source:The Lancet Oncology, Volume 19, Issue 4


      PubDate: 2018-04-12T09:29:51Z
       
  • Adjuvant anastrozole versus exemestane versus letrozole, upfront or after
           2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a
           randomised, phase 3 trial
    • Authors: Sabino Placido; Ciro Gallo Michelino Laurentiis Giancarlo Bisagni Grazia Arpino
      Abstract: Publication date: April 2018
      Source:The Lancet Oncology, Volume 19, Issue 4
      Author(s): Sabino De Placido, Ciro Gallo, Michelino De Laurentiis, Giancarlo Bisagni, Grazia Arpino, Maria Giuseppa Sarobba, Ferdinando Riccardi, Antonio Russo, Lucia Del Mastro, Alessio Aligi Cogoni, Francesco Cognetti, Stefania Gori, Jennifer Foglietta, Antonio Frassoldati, Domenico Amoroso, Lucio Laudadio, Luca Moscetti, Filippo Montemurro, Claudio Verusio, Antonio Bernardo, Vito Lorusso, Adriano Gravina, Gabriella Moretti, Rossella Lauria, Antonella Lai, Carmela Mocerino, Sergio Rizzo, Francesco Nuzzo, Paolo Carlini, Francesco Perrone
      Background Uncertainty exists about the optimal schedule of adjuvant treatment of breast cancer with aromatase inhibitors and, to our knowledge, no trial has directly compared the three aromatase inhibitors anastrozole, exemestane, and letrozole. We investigated the schedule and type of aromatase inhibitors to be used as adjuvant treatment for hormone receptor-positive early breast cancer. Methods FATA-GIM3 is a multicentre, open-label, randomised, phase 3 trial of six different treatments in postmenopausal women with hormone receptor-positive early breast cancer. Eligible patients had histologically confirmed invasive hormone receptor-positive breast cancer that had been completely removed by surgery, any pathological tumour size, and axillary nodal status. Key exclusion criteria were hormone replacement therapy, recurrent or metastatic disease, previous treatment with tamoxifen, and another malignancy in the previous 10 years. Patients were randomly assigned in an equal ratio to one of six treatment groups: oral anastrozole (1 mg per day), exemestane (25 mg per day), or letrozole (2·5 mg per day) tablets upfront for 5 years (upfront strategy) or oral tamoxifen (20 mg per day) for 2 years followed by oral administration of one of the three aromatase inhibitors for 3 years (switch strategy). Randomisation was done by a computerised minimisation procedure stratified for oestrogen receptor, progesterone receptor, and HER2 status; previous chemotherapy; and pathological nodal status. Neither the patients nor the physicians were masked to treatment allocation. The primary endpoint was disease-free survival. The minimum cutoff to declare superiority of the upfront strategy over the switch strategy was assumed to be a 2% difference in disease-free survival at 5 years. Primary efficacy analyses were done by intention to treat; safety analyses included all patients for whom at least one safety case report form had been completed. Follow-up is ongoing. This trial is registered with the European Clinical Trials Database, number 2006-004018-42, and ClinicalTrials.gov, number NCT00541086. Findings Between March 9, 2007, and July 31, 2012, 3697 patients were enrolled into the study. After a median follow-up of 60 months (IQR 46–72), 401 disease-free survival events were reported, including 211 (11%) of 1850 patients allocated to the switch strategy and 190 (10%) of 1847 patients allocated to upfront treatment. 5-year disease-free survival was 88·5% (95% CI 86·7–90·0) with the switch strategy and 89·8% (88·2–91·2) with upfront treatment (hazard ratio 0·89, 95% CI 0·73–1·08; p=0·23). 5-year disease-free survival was 90·0% (95% CI 87·9–91·7) with anastrozole (124 events), 88·0% (85·8–89·9) with exemestane (148 events), and 89·4% (87·3 to 91·1) with letrozole (129 events; p=0·24). No unexpected serious adverse reactions or treatment-related deaths occurred. Musculoskeletal side-effects were the most frequent grade 3–4 events, reported in 130 (7%) of 1761 patients who received the switch strategy and 128 (7%) of 1766 patients who received upfront treatment. Grade 1 musculoskeletal events were more frequent with the upfront schedule than with the switch schedule (924 [52%] of 1766 patients vs 745 [42%] of 1761 patients). All other grade 3–4 adverse events occurred in less than 2% of patients in either group. Interpretation 5 years of treatment with aromatase inhibitors was not superior to 2 years of tamoxifen followed by 3 years of aromatase inhibitors. None of the three aromatase inhibitors was superior to the others in terms of efficacy. Therefore, patient preference, tolerability, and financial constraints should be considered when deciding the optimal treatment approach in this setting.
      PubDate: 2018-04-12T09:29:51Z
       
  • Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma
           (BRIM8): a randomised, double-blind, placebo-controlled, multicentre,
           phase 3 trial
    • Authors: Michele Maio; Karl Lewis Lev Demidov Mario Igor Bondarenko Paolo
      Abstract: Publication date: April 2018
      Source:The Lancet Oncology, Volume 19, Issue 4
      Author(s): Michele Maio, Karl Lewis, Lev Demidov, Mario Mandalà, Igor Bondarenko, Paolo A Ascierto, Christopher Herbert, Andrzej Mackiewicz, Piotr Rutkowski, Alexander Guminski, Grant R Goodman, Brian Simmons, Chenglin Ye, Yibing Yan, Dirk Schadendorf
      Background Systemic adjuvant treatment might mitigate the high risk of disease recurrence in patients with resected stage IIC–III melanoma. The BRIM8 study evaluated adjuvant vemurafenib monotherapy in patients with resected, BRAF V600 mutation-positive melanoma. Methods BRIM8 was a phase 3, international, double-blind, randomised, placebo-controlled study that enrolled 498 adults (aged ≥18 years) with histologically confirmed stage IIC–IIIA–IIIB (cohort 1) or stage IIIC (cohort 2) BRAF V600 mutation-positive melanoma that was fully resected. Patients were randomly assigned (1:1) by an interactive voice or web response system to receive twice-daily adjuvant oral vemurafenib 960 mg tablets or matching placebo for 52 weeks (13 × 28-day cycles). Randomisation was done by permuted blocks (block size 6) and was stratified by pathological stage and region in cohort 1 and by region in cohort 2. The investigators, patients, and sponsor were masked to treatment assignment. The primary endpoint was disease-free survival in the intention-to-treat population, evaluated separately in each cohort. Hierarchical analysis of cohort 2 before cohort 1 was prespecified. This trial is registered with ClinicalTrials.gov, number NCT01667419. Findings The study enrolled 184 patients in cohort 2 (93 were assigned to vemurafenib and 91 to placebo) and 314 patients in cohort 1 (157 were assigned to vemurafenib and 157 to placebo). At the time of data cutoff (April 17, 2017), median study follow-up was 33·5 months (IQR 25·9–41·6) in cohort 2 and 30·8 months (25·5–40·7) in cohort 1. In cohort 2 (patients with stage IIIC disease), median disease-free survival was 23·1 months (95% CI 18·6–26·5) in the vemurafenib group versus 15·4 months (11·1–35·9) in the placebo group (hazard ratio [HR] 0·80, 95% CI 0·54–1·18; log-rank p=0·026). In cohort 1 (patients with stage IIC–IIIA–IIIB disease) median disease-free survival was not reached (95% CI not estimable) in the vemurafenib group versus 36·9 months (21·4–not estimable) in the placebo group (HR 0·54 [95% CI 0·37–0·78]; log-rank p=0·0010); however, the result was not significant because of the prespecified hierarchical prerequisite for the primary disease-free survival analysis of cohort 2 to show a significant disease-free survival benefit. Grade 3–4 adverse events occurred in 141 (57%) of 247 patients in the vemurafenib group and 37 (15%) of 247 patients in the placebo group. The most common grade 3–4 adverse events in the vemurafenib group were keratoacanthoma (24 [10%] of 247 patients), arthralgia (17 [7%]), squamous cell carcinoma (17 [7%]), rash (14 [6%]), and elevated alanine aminotransferase (14 [6%]), although all keratoacanthoma events and most squamous cell carcinoma events were by default graded as grade 3. In the placebo group, grade 3–4 adverse events did not exceed 2% for any of the reported terms. Serious adverse events were reported in 40 (16%) of 247 patients in the vemurafenib group and 25 (10%) of 247 patients in the placebo group. The most common serious adverse event was basal cell carcinoma, which was reported in eight (3%) patients in each group. One patient in the vemurafenib group of cohort 2 died 2 months after admission to hospital for grade 3 hypertension; however, this death was not considered to be related to the study drug. Interpretation The primary endpoint of disease-free survival was not met in cohort 2, and therefore the analysis of cohort 1 showing a numerical benefit in disease-free survival with vemurafenib versus placebo in patients with resected stage IIC–IIIA–IIIB BRAF V600 mutation-positive melanoma must be considered exploratory only. 1 year of adjuvant vemurafenib was well tolerated, but might not be an optimal treatment regimen in this patient population.
      PubDate: 2018-04-12T09:29:51Z
       
  • EMA guidance on radium-223 dichloride in prostate cancer
    • Authors: Elizabeth Gourd
      Abstract: Publication date: Available online 15 March 2018
      Source:The Lancet Oncology
      Author(s): Elizabeth Gourd


      PubDate: 2018-03-19T09:44:29Z
      DOI: 10.1016/s1470-2045(18)30216-x
       
  • ATLANTIC: a sea change in immunotherapy for oncogene-driven lung
           cancer'
    • Authors: Jessica J Lin; Justin F Gainor
      Abstract: Publication date: Available online 12 March 2018
      Source:The Lancet Oncology
      Author(s): Jessica J Lin, Justin F Gainor


      PubDate: 2018-03-19T09:44:29Z
      DOI: 10.1016/s1470-2045(18)30160-8
       
  • Vulvar field resection: innovative procedure or same old'
    • Authors: Tiffany Zigras; Allan Covens
      Abstract: Publication date: Available online 9 March 2018
      Source:The Lancet Oncology
      Author(s): Tiffany Zigras, Allan Covens


      PubDate: 2018-03-19T09:44:29Z
      DOI: 10.1016/s1470-2045(18)30110-4
       
  • Aiming for complete responses in renal-cell carcinoma
    • Authors: Viktor
      Abstract: Publication date: Available online 9 March 2018
      Source:The Lancet Oncology
      Author(s): Viktor Grünwald


      PubDate: 2018-03-19T09:44:29Z
       
  • Dasatinib in paediatric chronic myeloid leukaemias
    • Authors: Priya Venkatesan
      Abstract: Publication date: Available online 8 March 2018
      Source:The Lancet Oncology
      Author(s): Priya Venkatesan


      PubDate: 2018-03-19T09:44:29Z
      DOI: 10.1016/s1470-2045(18)30196-7
       
  • Colorectal adenoma risk in childhood cancer survivors
    • Authors: Talha Khan Burki
      Abstract: Publication date: Available online 8 March 2018
      Source:The Lancet Oncology
      Author(s): Talha Khan Burki


      PubDate: 2018-03-19T09:44:29Z
      DOI: 10.1016/s1470-2045(18)30197-9
       
 
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
 
Home (Search)
Subjects A-Z
Publishers A-Z
Customise
APIs
Your IP address: 54.224.44.168
 
About JournalTOCs
API
Help
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-